Pharmaceutical Patents

A composition patent on the active ingredient (API) itself is the most valuable pharmaceutical patent. It covers the specific chemical compound (or a genus including it) regardless of formulation, dosage form, or indication. A composition patent typically issues during or shortly after clinical development and expires 20 years from the U.S. filing date. Patent term extension (Hatch-Waxman, 35 U.S.C. § 156) can restore up to 5 years of term lost to FDA regulatory review, capped so remaining term after FDA approval does not exceed 14 years.

A formulation patent covers a specific pharmaceutical composition: the drug combined with particular excipients, carriers, or in a specific dosage form (extended-release, film-coated tablet, transdermal patch, injectable suspension, etc.). Formulation patents are often filed and prosecuted after the API patent and can extend effective exclusivity well beyond the API patent expiration — a key element of 'patent thickets.' Innovators file formulation patents on every commercially significant dosage form.

A method-of-treatment patent covers the use of a drug to treat a specific disease or condition. These patents are infringed by prescribing physicians (direct infringement) and by the drug company selling the labeled indication (induced infringement under § 271(b)). In the U.S., method-of-treatment patents face § 101 eligibility risk under Mayo Collaborative Services v. Prometheus Laboratories, Inc. (S.Ct. 2012) — the Mayo two-step test scrutinizes whether claims merely recite a natural relationship between a drug's effect and a medical condition, without an inventive concept beyond administering the drug. Well-drafted claims tie the method to a specific patient population, specific biomarker-based selection, or specific dosing protocol to distinguish from natural phenomena.

A process patent covers the method of synthesizing or manufacturing the active ingredient or formulation. Process patents are difficult to detect (the manufacturing process is not observable in the final product), but under 35 U.S.C. § 271(g), importing a product made by a patented U.S. process infringes the process patent. This extends infringement protection to generics manufactured abroad using the patented process. Process patents become more valuable as API synthesis complexity increases.

A metabolite patent covers a naturally occurring or drug-generated metabolite — the compound the body converts the drug into. The patentability of metabolites has been significantly limited by § 101 natural phenomena doctrine after Mayo and Association for Molecular Pathology v. Myriad Genetics (S.Ct. 2013). A metabolite that is a naturally occurring compound and is merely 'discovered' in the body is likely patent-ineligible. Metabolite patents covering novel synthetic metabolites or specific dosage/concentration-correlated methods retain more viability.

A combination patent covers a fixed-dose combination (FDC) of two or more active ingredients. If the combination produces a synergistic effect not predictable from the individual components, the combination can be patentable even if the individual APIs are in the prior art. Combination patents are commonly used in HIV antiretroviral therapy, cardiovascular drugs, and oncology.

Many drug APIs can exist in multiple crystalline forms (polymorphs) with different physical properties (solubility, stability, bioavailability). A polymorph patent covers a specific crystal form. If the polymorph has unexpected advantages (improved bioavailability, better stability, lower hygroscopicity), it may be patentable as non-obvious. Polymorph patents are frequently challenged by generics as obvious — the court considers whether a POSITA would have been motivated to try the specific polymorph and have a reasonable expectation of success.

What Hatch-Waxman does

The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) created the current framework for generic drug approval and pharmaceutical patent protection. It has two main components: (1) The ANDA (Abbreviated New Drug Application) pathway allows a generic manufacturer to obtain FDA approval by demonstrating bioequivalence to an approved brand-name drug, without repeating the brand-name's clinical trials. (2) Patent Term Extension under § 156 allows a brand-name drug maker to extend the term of one patent per drug by up to 5 years to compensate for the time spent in FDA regulatory review, provided the remaining term after FDA approval does not exceed 14 years.

Orange Book listing

When the FDA approves a new drug application (NDA), the brand-name company must list in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) all patents that claim the drug substance (API), drug product (formulation, dosage form), or a method of use for which approval was granted — and for which a claim of patent infringement could reasonably be asserted against a generic. Method-of-use patents must be listed only for methods for which approval was granted. Improperly listed patents (listing patents that don't actually claim the approved drug or method) can give rise to antitrust claims and FDA regulatory penalties.

ANDA certification types

A generic manufacturer filing an ANDA for a drug with Orange Book-listed patents must certify with respect to each listed patent: (I) no patent has been listed; (II) the listed patent has expired; (III) the ANDA will not be effective until the listed patent expires (a voluntary 'Paragraph III certification'); or (IV) the listed patent is invalid, unenforceable, or will not be infringed ('Paragraph IV certification'). A Paragraph IV certification is considered an act of patent infringement under 35 U.S.C. § 271(e)(2), triggering the brand-name's right to sue immediately.

30-month stay

If the brand-name company sues within 45 days of receiving notice of a Paragraph IV certification, the FDA is automatically prohibited from approving the ANDA for 30 months (the '30-month stay'), unless the court rules the patents invalid or not infringed before that time. The 30-month stay is the primary litigation mechanism for brand-name companies to delay generic entry. Brand-name companies commonly list multiple patents in the Orange Book to trigger multiple 30-month stays (each new patent listing can trigger a new stay if added before the ANDA is filed, under the pre-2003 rules — the 2003 MMA limited this to one 30-month stay per ANDA).

180-day exclusivity for first filer

The first generic manufacturer to file a Paragraph IV ANDA earns 180 days of market exclusivity — the FDA cannot approve any other generic ANDA for the same drug during those 180 days. This exclusivity makes first-filer status extremely valuable. Generic companies race to file first. The 180-day exclusivity can be forfeited (and is forfeited to a subsequent first-filer) if the first filer fails to bring the drug to market, receives a final court decision finding the listed patents invalid or not infringed, or fails to market within 75 days of an appellate court affirmance of invalidity or non-infringement.

Statutory framework

Biologic drugs (large-molecule drugs including monoclonal antibodies, vaccines, proteins) are approved under the Public Health Service Act (PHSA) § 351, not the FDCA used for small-molecule drugs. The Biologics Price Competition and Innovation Act (BPCIA, 2010, part of the ACA) created the biosimilar approval pathway.

Biosimilar exclusivity

A reference biologic drug gets 12 years of data exclusivity under BPCIA — no biosimilar application can be approved until 12 years after the reference product's licensure, regardless of patent status. This is far more generous than the 5-year NCE data exclusivity for small molecules.

Patent Dance

The BPCIA created a complex patent information-sharing procedure (the 'patent dance') between biosimilar applicants and brand-name biologics companies. The biosimilar applicant shares its abbreviated BLA and manufacturing information; the brand-name company identifies patents it believes would be infringed; parties negotiate which patents to litigate. The patent dance is optional (Sandoz v. Amgen, S.Ct. 2017).

Orange Book vs Purple Book

Small-molecule drugs: Orange Book. Biologics: FDA Purple Book (Biological Product Purple Book). The Orange Book triggers Hatch-Waxman 30-month stays; the Purple Book has no equivalent automatic stay mechanism.

Section 101 and antibody claims

After Amgen Inc. v. Sanofi (S.Ct. 2023), the Supreme Court unanimously invalidated Amgen's genus claims covering all antibodies that bind to a specific site on PCSK9 and block its function. The Court held that a functional genus claim covering potentially millions of antibodies was not fully enabled — the specification enabled only a subset. This decision significantly affects how biologic and antibody patent claims must be drafted to withstand enablement challenges.